Outcomes after recurrence on neoadjuvant chemo-immunotherapy (NCIT) in patients (pts) with high-risk early-stage triple-negative breast cancer (eTNBC).
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Chiara Corti, Qingchun Jin, Catherine Stever, Alyssa R. Martin, Cyntholia Helena Okui, Nisar Ahmad, Nadine M. Tung, Natalie Sinclair, Meredith Gail Faggen, Sarah Sinclair, Maria Constantinou, Steve Lo, Jane Lowe Meisel, Eric P. Winer, Giuseppe Curigliano, Nancy U. Lin, Elizabeth A. Mittendorf, Nabihah Tayob, Sara M. Tolaney, Ana Christina Garrido-Castro
Institutions: Dana-Farber Cancer Institute, Berkshire Medical Center, Berkshire Health Systems, Beth Israel Deaconess Medical Center, Brown University, Rhode Island Hospital, Stamford Hospital, Emory University, Winship Cancer Institute, Yale Cancer Center, University of Milan, European Institute of Oncology
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
Award: G1122220156
OpenAlex ID: W7162569235
Cites:
Cited by:
Related to: